Literature DB >> 19764835

Socioeconomic differences in preferences and willingness-to-pay for insulin delivery systems in type 1 and type 2 diabetes.

Camila Guimarães1, Carlo A Marra, Lindsey Colley, Sabrina Gill, Scot Simpson, Graydon Meneilly, Regina H C Queiroz, Larry D Lynd.   

Abstract

BACKGROUND: An evaluation of patients' preferences is necessary to understand the demand for different insulin delivery systems. The aim of this study was to investigate the association between socioeconomic status (SES) and patients' preferences and willingness to pay (WTP) for various attributes of insulin administration for diabetes management.
METHODS: We conducted a discrete choice experiment (DCE) to determine patients; preferences and their WTP for hypothetical insulin treatments. Both self-reported annual household income and education completed were used to explore differences in treatment preferences and WTP for different attributes of treatment across different levels of SES.
RESULTS: The DCE questionnaire was successfully completed by 274 patients. Overall, glucose control was the most valued attribute by all socioeconomic groups, while route of insulin delivery was not as important. Patients with higher incomes were willing to pay significantly more for better glucose control and to avoid adverse events compared to lower income groups. In addition, they were willing to pay more for an oral short-acting insulin ($Can 71.65 [95% confidence interval, $40.68, $102.62]) compared to the low income group ($Can 9.85 [95% confidence interval, 14.86, 34.56; P < 0.01]). Conversely, there were no differences in preferences when the sample was stratified by level of education.
CONCLUSIONS: This study revealed that preferences and WTP for insulin therapy are influenced by income but not by level of education. Specifically, the higher the income, the greater desire for an oral insulin delivery system, whereas an inhaled route becomes less important for patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19764835     DOI: 10.1089/dia.2009.0034

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN: 1520-9156            Impact factor:   6.118


  13 in total

Review 1.  Valuing Meta-Health Effects for Use in Economic Evaluations to Inform Reimbursement Decisions: A Review of the Evidence.

Authors:  Richard De Abreu Lourenco; Marion Haas; Jane Hall; Rosalie Viney
Journal:  Pharmacoeconomics       Date:  2017-03       Impact factor: 4.981

2.  Prescribing of antidiabetic therapies in Ireland: 10-year trends 2003-2012.

Authors:  N L Zaharan; D Williams; K Bennett
Journal:  Ir J Med Sci       Date:  2013-09-07       Impact factor: 1.568

Review 3.  Patient preferences for the treatment of type 2 diabetes: a scoping review.

Authors:  Susan M Joy; Emily Little; Nisa M Maruthur; Tanjala S Purnell; John F P Bridges
Journal:  Pharmacoeconomics       Date:  2013-10       Impact factor: 4.981

Review 4.  The patient perspective of diabetes care: a systematic review of stated preference research.

Authors:  Lill-Brith von Arx; Trine Kjeer
Journal:  Patient       Date:  2014       Impact factor: 3.883

5.  Agreement between aggregate and individual-level measures of income and education: a comparison across three patient groups.

Authors:  Carlo A Marra; Larry D Lynd; Stephanie S Harvard; Maja Grubisic
Journal:  BMC Health Serv Res       Date:  2011-03-31       Impact factor: 2.655

6.  The effect of out-of-pocket costs and financial rewards in a discrete choice experiment: an application to lifestyle programs.

Authors:  Johanna O P Wanders; Jorien Veldwijk; G Ardine de Wit; Huberta E Hart; Paul F van Gils; Mattijs S Lambooij
Journal:  BMC Public Health       Date:  2014-08-23       Impact factor: 3.295

7.  Willingness to pay for antiretroviral drugs among HIV and AIDS clients in south-east Nigeria.

Authors:  Chinyere Mbachu; Chijioke Okoli; Obinna Onwujekwe; Fabian Enabulele
Journal:  Health Expect       Date:  2017-08-14       Impact factor: 3.377

8.  Canadian genetic healthcare professionals' attitudes towards discussing private pay options with patients.

Authors:  Vanessa Di Gioacchino; Sylvie Langlois; Alison M Elliott
Journal:  Mol Genet Genomic Med       Date:  2019-02-02       Impact factor: 2.183

Review 9.  Preference for pharmaceutical formulation and treatment process attributes.

Authors:  Katie D Stewart; Joseph A Johnston; Louis S Matza; Sarah E Curtis; Henry A Havel; Stephanie A Sweetana; Heather L Gelhorn
Journal:  Patient Prefer Adherence       Date:  2016-07-27       Impact factor: 2.711

10.  Education and patient preferences for treating type 2 diabetes: a stratified discrete-choice experiment.

Authors:  Ellen M Janssen; Daniel R Longo; Joan K Bardsley; John Fp Bridges
Journal:  Patient Prefer Adherence       Date:  2017-10-06       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.